(Q37867668)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Combination therapy in pulmonary arterial hypertension: do we have the right strategy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

main subject

arterial hypertension

0 references

author

Luke S. Howard

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Bhashkar Mukherjee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Respiratory Medicine

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

191-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21510730%20AND%20SRC:MED&resulttype=core&format=json

Pulmonary arterial hypertension in France: results from a national registry

29 January 2020

cites work

1 reference

An epidemiological study of pulmonary arterial hypertension.

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

21 January 2018

1 reference

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

21 January 2018

1 reference

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

Treating pulmonary arterial hypertension: is it worth it?

21 January 2018

1 reference

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension

21 January 2018

1 reference

Future perspectives for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

21 January 2018

1 reference

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

21 January 2018

1 reference

Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart.

21 January 2018

1 reference

Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation

21 January 2018

1 reference

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade

21 January 2018

1 reference

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension

21 January 2018

1 reference

Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats

21 January 2018

1 reference

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies

21 January 2018

1 reference

Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart.

21 January 2018

1 reference

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis

21 January 2018

1 reference

A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology

21 January 2018

1 reference

Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed

21 January 2018

1 reference

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue

21 January 2018

1 reference

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

21 January 2018

1 reference

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

21 January 2018

1 reference

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension

21 January 2018

1 reference

Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension

21 January 2018

1 reference

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

21 January 2018

1 reference

Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy

21 January 2018

1 reference

Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study

21 January 2018

1 reference

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.

21 January 2018

1 reference

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

21 January 2018

1 reference

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease

21 January 2018

1 reference

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

21 January 2018

1 reference

Pulmonary Arterial Hypertension

21 January 2018

1 reference

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

21 January 2018

1 reference

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling

21 January 2018

1 reference

A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

21 January 2018

1 reference

Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy

21 January 2018

1 reference

Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan

21 January 2018

1 reference

Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol

21 January 2018

1 reference

Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy

21 January 2018

1 reference

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension

21 January 2018

1 reference

Sildenafil treatment for portopulmonary hypertension

21 January 2018

1 reference

Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension

21 January 2018

1 reference

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

21 January 2018

1 reference

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value

21 January 2018

1 reference